Welcome to our dedicated page for Organon & Co. news (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co. stock.
Organon & Co. (OGN) is a science-based global pharmaceutical company dedicated to developing and delivering essential health solutions. Founded in Oss, the Netherlands, Organon originally gained fame for pioneering the birth control pill, which revolutionized women's health. Over the years, the company expanded significantly and was acquired by Schering-Plough, and later by Merck, continuing its legacy as MSD in the Netherlands.
Today, Organon operates with a robust portfolio comprising women's health, biosimilars, and established medicines. The company focuses on providing prescription therapies that address a wide range of health needs, particularly in women's health. Organon's product offerings include innovations in contraception, fertility treatments, and menopause management.
In addition to women's health, Organon is committed to advancing the field of biosimilars - biologically similar products to existing branded drugs that promise to enhance patient access to key treatments. The company's established brands, which include a variety of well-known medications, continue to be a core revenue driver. Geographically, Organon derives most of its revenue from Europe and Canada, followed by the United States, and then the Asia Pacific and Japan regions.
Organon remains at the forefront of pharmaceutical innovation, driven by a mission to improve health outcomes globally. The company's strategic partnerships and continued investment in research and development reflect its commitment to addressing some of the most pressing health challenges of our time.
Organon (NYSE: OGN) is set to release its Q1 2023 financial results on May 4, 2023, before a scheduled webcast and conference call at 8:30 a.m. EDT. The live call can be accessed via the company's website, with a replay available two hours post-event. Institutional investors and analysts must register in advance to join the call.
Organon, headquartered in Jersey City, New Jersey, focuses on women's health, offering over 60 products across various therapeutic areas. The company aims to invest in innovation and strengthen its global presence, supporting growth and collaboration opportunities in the biopharmaceutical sector.
On April 19, 2023, Lifezone Metals announced the initiation of an off-take marketing process for nickel, copper, and cobalt from its Kabanga Project, believed to be among the world's largest and highest-grade nickel deposits. This move follows a Business Combination Agreement with GoGreen Investments Corporation (NYSE: GOGN). Lifezone aims to support the clean energy transition through its proprietary Hydromet Technology, which offers a low-carbon alternative to traditional smelting. The company holds marketing rights for up to 40% of the Kabanga Project's total production. RBC Capital Markets will oversee the marketing process, which is critical for monetizing the project amid rising demand from electric vehicle and battery manufacturers.
Organon (NYSE: OGN) has launched a global initiative named “Her Plan is Her Power” with a funding of
FAQ
What is the current stock price of Organon & Co. (OGN)?
What is the market cap of Organon & Co. (OGN)?
What is Organon & Co. known for?
What are the main product areas of Organon & Co.?
Where does Organon & Co. generate most of its revenue?
Who previously acquired Organon & Co.?
What types of products does Organon offer in women's health?
What are biosimilars?
How does Organon & Co. contribute to global health?
Has Organon & Co. been involved in any recent significant projects or initiatives?
What is the history of Organon & Co. in the Netherlands?
What is the significance of Organon's established brands?
